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Background: First dose observation for cardiac effects is required for fingolimod.
Previous results in patients with relapsing remitting multiple sclerosis (RRMS) suggest
that transient bradycardia and conduction abnormalities during the observation phase
are rare, benign and reversible. Prior analyses corroborate these findings. The present
large scale dataset allows subgroup analyses for differences in the incidence of cardiac
findings depending on patient characteristics.
Methods: START was an open-label, multi-center study that enrolled 6,998 RRMS
patients. Primary endpoints were incidence of bradycardia (heart rate < 45 bpm) and
second-/third-degree atrioventricular (AV) block during treatment initiation. Subgroup
analyses were performed according to age, gender, body mass index (BMI), baseline
expanded disability status scale (EDSS), and concomitant medication to determine the
impact of these variables on cardiac outcomes parameters.
Results: 63 patients (0.9%) developed bradycardia (<45 bpm), 120 patients (1.7%)
had a second-degree Mobitz I (Wenkebach) block and/or 2:1 AV block. One case of an
asymptomatic third-degree AV block occurred. NoMobitz II AV block was observed. After
1 week, no second-/third-degree AV block was observed. The incidence of second- or
third-degree AV blocks was significantly higher in older patients (≥50 years; p = 0.014
vs. patients 35–49 years). Second- or third-degree AV blocks were more frequent in
females (87.5% of all patients with a second- or third-degree AV block; p < 0.001), while
bradycardia occurred more often in males (58.7% of all bradycardia events; p < 0.001).
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Furthermore, patients with a BMI below 25 had a higher incidence of second- or
third-degree AV block.
Conclusions: In summary, transient bradycardia and AV conduction abnormalities
after the first dose of fingolimod were rare and asymptomatic. When compared to
females, male patients might have a higher risk for bradycardia during treatment
initiation, presumably due to a lower resting heart rate. Furthermore, a low heart rate
before treatment initiation, low body weight, or low BMI possibly increases the risk for
bradycardia. Second- or third-degree AV blocks were more frequent in females, older
patients and patients with a low BMI. Nevertheless, these cardiac events remained rare
and benign, confirming the favorable cardiac safety profile of fingolimod upon treatment
initiation in MS patients without cardiovascular comorbidities.
Keywords: fingolimod, first dose, electrocardiogram, cardiac effects, bradycardia, atrioventricular conduction
INTRODUCTION
Fingolimod (FTY720, brand name Gilenya R©) has been approved
for the treatment of relapsing remitting multiple sclerosis
(RRMS). It exerts its therapeutic effects via modulation of
sphingosine-1-phosphate (S1P-) receptors on lymphocytes (1–
5). As receptors of this class, predominantly S1P1, are also
expressed on atrial myocytes (6), fingolimod mediates a transient
decrease in heart rate and prolongation of atrioventricular (AV)
conduction that is limited to treatment initiation (7–10). The
first dose of fingolimod was found to result in an increase
in parasympathetic activity. It was suggested that this effect is
responsible for an initial heart rate decline (11, 12) and measures
of parasympathetic activity could be a predictive marker of
first dose events (13, 14). Furthermore, cardiac autonomic tone
at baseline was found to predict the magnitude of heart rate
decrease (15).
In the pivotal trials, first-degree AV blocks (prolonged PR
interval) following drug initiation were detected in 4.7% of
patients on fingolimod 0.5mg and 1.7% of patients on placebo.
Second-degree AV block was detected in 0.2% patients on
fingolimod 0.5mg. The conduction abnormalities were typically
transient, asymptomatic, and resolved within 24 h on treatment.
START was a prospective study that aimed to assess the cardiac
safety of fingolimod first dose in detail in a much larger
cohort compared to previous studies in daily practice treatment
circumstances (14, 16–22). The study followed the EU label
first-dose observation recommendation by obtaining a Holter
ECG for 6 h in addition to clinical monitoring and pre-/post
first dose 12-lead ECG. Previously published results of an
interim analysis with 3,951 patients have shown that clinically
Abbreviations: AE, Adverse event; AV, Atrioventricular conduction; BMI, Body
Mass Index; bpm, Beats per minute; CI, Confidence Interval; DSMB, Data Safety
Monitoring Board; ECG, Electrocardiogram; EDSS, Expanded Disability Status
Scale; EU, European Union; EUDRACT, European Clinical Trials Database;
FTY720, Fingolimod; HR, Heart rate; i.e., id est; MedDRA, Medical Dictionary
for Regulatory Activities; mg, milligram; mmol, millimol; ms, millisecond; MS,
Multiple Sclerosis; PT, Preferred Term; RRMS, Relapsing remitting multiple
sclerosis; S1P, Sphingosine-1-phosphate; SAE, Serious adverse event; SD, Standard
deviation; SOC, System Organ Class; US, United States.
relevant cardiac events did not correspond with abnormalities
on continuous ECG monitoring and conduction abnormalities
as demonstrated by Holter ECG usually remained clinically
asymptomatic (23). The results suggest that continuous Holter
ECG monitoring after fingolimod first dose likely may not
add clinically relevant value to patient safety with respect to
bradycardia or conduction abnormalities in a general RRMS
population without cardiovascular comorbidities.
This final analysis was conducted after enrolment of another
3,000 patients, resulting in 6.998 enrolled patients. With its far
larger and unique sample size it was aimed to substantiate the
findings of the interim analyses and to investigate the impact
of patient or disease characteristics like age, gender, BMI, EDSS
status, or concomitant medication on the cardiac outcomes
parameters studied.
PATIENTS AND METHODS
Study Design, Approvals, and Participants
START (NCT01585298; www.clinicaltrials.gov) was an open-
label, multi-center study in Germany in patients with RRMS
receiving fingolimod at a daily dose of 0.5mg. Its purpose
was (a) to assess cardiac safety of first dose fingolimod
with a special focus on bradycardia and AV conduction
abnormalities, and (b) to analyze individual arrhythmic episodes
more extensively in order to evaluate the clinical relevance
of continuous ECG monitoring. The study protocol was
approved by the respective state and institutional ethical
standards committees at all participating sites (Competent ethics
committee: Ethikkommission der Ärztekammer Nordrhein;
EUDRACT No. 2012-000653-32-DE). Patients had to give
written informed consent. The inclusion and exclusion criteria
have been published previously (23). Patients were allowed to
repeatedly participate in the START study in case they had
previously discontinued fingolimod.
Between June 2012 and December 2016, 6,998 patients were
enrolled in 278 centers in Germany, of which 6,961 (99.5%)
completed the study. Sample size calculation was revised based
on the observed incidence of 0.963% of a second-degree or higher
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AV block in the first 1,000 patients enrolled, which was lower
than originally anticipated. With a sample size of 7,000, a two-
sided 95% confidence interval for a single proportion extended
0.0023 or 0.23% from the observed proportion for an expected
proportion of 0.00963.
Endpoints
Primary endpoints were the incidence of bradycardia (heart
rate <45 bpm) as measured by pulse palpation by study
personnel, and the incidence conduction block (second-degree
AV block type Mobitz I (Wenkebach block), second-degree AV
block type Mobitz II second degree, 2:1 AV block, and third-
degree AV block) during the 6 h Holter monitoring period.
Secondary endpoints included the incidence of other conduction
abnormalities such as first-degree AV block (PR-interval
prolongation), and QTc prolongation [Fridericia correction of
the QT intervals: QTc= QT/third root [RR]].
Furthermore, the incidence of adverse events (AE), serious
adverse events (SAE), AE suggestive for cardiac origin, and
the incidence of overnight hospitalization was determined. The
occurrence of any cardiac symptoms was assessed in patients with
an identified second- or higher degree AV block. Furthermore,
continuous ECG recordings of patients with an AV block were
evaluated rigorously. The duration of pauses (RR intervals)
and the minimal heart rate during a second-degree AV block
were determined post hoc by the cardiologist. Holter ECG
data of patients with cardiac symptoms were assessed for any
abnormalities that might have predicted the symptoms. Details
on the endpoint definitions have been published previously.
Subgroup Analyses
Subgroup analyses were performed according to age, gender,
BMI, baseline EDSS, use of concomitant medication known
to prolong the QT/QTc interval, and use of disease-modifying
treatment to determine the impact of these variables on cardiac
outcome parameters (incidence of bradycardia and incidence of
AV block second-degree or higher). Subgroup analyses according
to gender were also performed for the incidence of QTc
interval prolongation.
Study Procedures
Patients were assessed at screening, pre-dose, post-dose, and end-
of-study (after 7 days). Prior to the first dose of fingolimod a 12-
lead standard ECGwas recorded. First dosemonitoring consisted
of continous Holter monitoring for 6 h. At day 7 another 12-lead
ECGwas recorded. The study procedures were described in detail
in an earlier publication.
Statistics
Results of STARTwere analyzed using a logistic regressionmodel,
see Supplemental Tables 1, 2 for details. Where indicated,
additional statistical tests were performed using Student’s t-test
or Fisher’s exact test.




Mean ± SD 39.2 ± 10.5
Age groups in years, n (%)
18–34 2,504 (35.8)
35–49 3,234 (46.2)




Body mass index (kg/m²)





≤ 30 1,146 (16.4)
Relevant comorbidities
History of diabetes, n (%) 123 (1.8)
History of hypertension, n (%) 803 (11.7)
EDSS
Mean ± SD (n = 6,960) 2.7 ± 1.6
Missing 38 (0.5)
0–3.5 5,331 (76.2)
> 3.5–6 1,370 (19.6)
> 6 259 (3.7)




Study Patients and Conduct
The majority of the patients were seen by office-based
neurologists. Baseline demographics and MS history are
presented in Table 1. A Holter ECG was recorded at visit 2 in
6,925 (99%) out of 6,996 patients who received fingolimod. Two
patients of the 6,998 enrolled persons did not receive the study
drug (Figure 1).
Changes in Heart Rate
On average, patients receiving the first dose of fingolimod
experienced a transient decline in heart rate. 89.5% of the patients
reached the nadir before the end of the 6 h post-dose observation
period (mean 3.7 h; SD 1.16). In 63 patients (0.9%) heart rate
dropped below 45 bpm (95%-CI: 0.68–1.12) during treatment
initiation. The average pre-dose heart rate of these patients was
58.8 ± 9.10 bpm. At visit 3, bradycardia was observed in 5
patients (0.07%) (see Table 2). Table 3 presents the heart beat
dynamics during treatment initiation by time of the lowest heart
rate measurement, by presence of bradycardia and by presence of
AV block.
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FIGURE 1 | Patient disposition.









No bradycardia, n (%) 6,991 (99.99%) 6,933 (99.10%) 6,974 (99.93%)
Bradycardia with
HR<45 bpm, n (%)
1 (0.01%) 63 (0.90%) 5 (0.07%)
Male patients had a significantly higher incidence of
bradycardia (1.78%) than females (0.53%; p < 0.001; Figure 2).
These events occurred primarily during the first 5 h. Of note,
baseline heart rates in female patients were lower than those
in male patients (72.5 vs. 74.7; p < 0.0001) and incidence of
bradycardia was significantly higher in patients with a pre-dose
heart rate below 70 bpm. The maximum decline in heart rate was
not different between males and females (p= 0.9094).
Patients with an EDSS at baseline over 6 had a significantly
higher incidence of bradycardia (1.2%) vs. patients with an EDSS
between 3.5 and 6 (0.3%; p= 0.076; Figure 2).
The incidence of bradycardia was lowest in the subgroup
of patients with a BMI of ≥30. Furthermore, higher weight
was significantly correlated with a higher minimum heart rate
in the total population (p < 0.01). Analysis by age subgroups
revealed no differences in the incidence of bradycardia in any
age category. Subgroup analysis of patients with vs. without
concomitant medication known to prolong QT intervals (e.g.,
SSRI, tricyclic antidepressants, amantadine) (see Table 4), of
patients with vs. without prior disease-modifying therapy (e.g.,
beta-interferons, glatiramer acetate, natalizumab) showed no
significant differences for bradycardia or AV block (data not
shown), which is in line with previous studies regarding
SSRIs (24).
AV Conduction Abnormalities
Slowed AV conduction (i.e., first-degree AV block: PR-interval
>200ms) was observed in 124 patients (1.8%) before and 308
patients (4.4%) after the first dose of fingolimod. At visit 3, the
incidence of a first-degree AV block was identical to that before
treatment initiation (1.8% of patients) (see Table 5).
In 120 patients, a second-degree AV block was observed after
treatment initiation. Of these, 117 patients (1.67%) had a Mobitz
type I second-degree AV block. 43 type 2:1 blocks were identified
in 42 patients (0.61%), with 39 patients having both a Mobitz
type I and a 2:1 block within the observation period, and three
patients exhibiting a 2:1 AV block only. No episode of clear AV
block type Mobitz II was observed. An episode of a short lasting
third-degree AV block was detected in a 55 years old woman 3 h
38min after the first dose of fingolimod. The duration of this
third-degree AV block was 4,750ms. No clinical symptoms were
observed. The patient was monitored overnight and fingolimod
treatment was withdrawn. No AV block was observed the day
after the first dose of fingolimod in this patient. At visit 3, 12-lead
ECG did not reveal any second- or third-degree AV block in
any patient.
Of the 120 patients with a second- or third-degree AV block
during treatment initiation, 105 were females (2.10% of all
females) and 15 males (0.7%; p < 0.001). The highest incidence
(2.5%) was observed in patients with a very low BMI (< 18.5) and
the lowest incidence (0.6%) in patients with a high BMI (≥30; p
= 0.015; Figure 2).
Considering all second- or third-degree AV blocks, patients
between the age of 18 and 49 had a significantly lower
incidence (1.6/1.5%) compared to patients ≥50 years (2.5%; p
= 0.015/0.014). No significant difference in the incidence of AV
block (second- or third-degree) was observed in the different
EDSS subgroups (Figure 2) or between patient groups with pre-
dose heart rate below and over 70 bpm. Subgroup analysis
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Lowest post-dose heart ratea
(bpm) mean (range)
Maximum decline in heart ratea
(bpm) mean (SD)
Fingolimod, N = 6,985*
Overall population
Overall population 6,985* (100.0) 74.1 (42–132) 66.2 (40–120) 11.9 (8.52)
By time of lowest heart rate
Patients with lowest heart rate at < 6 h 6,265 (89.7) 74.0 (42–132) 66.0 (40–120) 12.0 (8.46)
Patients with lowest heart rate at 6 h 720 (10.3) 74.5 (47–120) 63.6 (38–90) 10.9 (8.94)
By presence of bradycardia
Patients with bradycardia 63 (0.9) 58.8 (42–91) 46.6 (31–68) 16.7 (9.36)
By presence of second-degree AV block
Patients with second-degree AV block 120 (1.7) 73.9 (53–100) 65.2 (46–93) 12.9 (8.69)
aAs measured by on-site study personnel.
*Only patients with values at baseline pre-dose and post-dose are included.
of patients with vs. without concomitant medication known
to prolong QT intervals, of patients with vs. without disease-
modifying therapy, and START repeaters vs. non-repeaters
showed no significant differences by group (data not shown).
On average, the second-degree AV block became manifest
3.49 h after drug intake (SD 1.17; range 0.42–5.87; Figure 3). It
always resolved spontaneously. In female patients, the mean time
to first occurrence was 3.61 h (SD = 1.12), while in males it was
2.68 h (SD = 1.20) (p = 0.0034). The mean (SD) minimal heart
rate during second-degree AV block as assessed by Holter ECG
(mean of 10 consecutive beats) was 50.91± 9.42 bpm (range 34–
80 bpm; Figure 4) with no significant difference between males
and females (p = 0.6955). The minimum heart rate of patients
with second-degree AV block as measured by study personnel
was 58.76 for males and 61.14 for females (p = 0.2682). The
longest pause observed in association with second-degree AV
block was 2,598ms, the upper limit of the 95%-CI was below
2,000ms. The mean value of the longest pause was 1,902.6 (SD
276.8; Figure 5) with no significant difference between males and
females (p= 0.1526).
Effects on Repolarization
Applying >450ms in men and >470ms in women as a
conservative threshold, only six men and seven women had
QTc intervals above their respective thresholds after fingolimod
intake. All of these patients continued with the study medication.
No patient had a QTc interval exceeding 500ms, which would
have warranted overnight monitoring as defined in the current
EU label.
A linear trend with age could be observed for prolonged QTc
intervals, as defined above. In the age group 18–34 the incidence
was 0.10%, in the age group 35–49 years 0.5%, and in the oldest
population (50 years and older) 0.7% (p = 0.0022). Pairwise
comparisons showed that the incidence in the youngest age group
compared with the two older age groups was significantly lower
(data not shown).
At visit 3, QT/QTc prolongation was observed in 13
patients, with higher incidence in males (0.39%) than
in females (0.10%; thresholds for QTc were >450 and
>470ms, respectively).
Adverse Events and Cardiac Symptoms
AEs were observed in 2.288 patients (32.7%) and 160 patients
(2.3%) experienced SAEs (Table 6). No deaths occurred.
The most frequent types of AEs causing discontinuation of
medication were cardiac and nervous system disorders (0.4
and 0.11%, respectively). Symptoms reported as AE during the
6 h monitoring suggestive of cardiac events occurred in 205
patients (2.93%, Table 3). Females did experience significantly
more cardiac adverse events, 7.41 vs. 5.98% (p= 0.0311).
Two cases of symptomatic second-degree AV block with
palpitations and dizziness and four cases of symptomatic
bradycardia were observed. Symptoms of bradycardia were
fatigue, dizziness, chest discomfort, and vertigo. Neither syncope
nor episodes of dyspnoea were observed. None of the patients
with cardiac symptoms had a pause longer than 2,000ms. No
supraventricular tachycardias were observed. Four patients had
more than 1,000 ventricular extra beats (VES) and another 4
patients had between 100 and 1,000 VES. 10–100 VES were
observed in 22 patients and <10 VES in 174 patients. Paired
VES occurred in only two patients (one couplet and one triplet).
Salves or R on T phenomena were not detected. Bigeminus or
trigeminus were present in 14 patients and 10 patients presented
with sinustachycardia of >130 bpm.
In total, 69 patients (0.99%) were hospitalized overnight due
to any cardiac adverse event that started during day 1 after first
dose administration.
DISCUSSION
This final analysis of the START study demonstrates that only
0.9% of the patients developed bradycardia after treatment
initiation. Symptomatic bradycardia was observed in 0.06%.
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FIGURE 2 | Cardiac outcomes by subgroups. (A–E) Subgroups for patients with AV Blocks 2nd degree or higher. (F–J) Subgroups for patients with bradycardia.
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Symptoms were always mild and transient (without the need
of any treatment). Episodes of second-degree AV block (Mobitz
Type I and 2:1) were detected in 1.70% of the patients and a
third-degree AV block in one patient. Despite the large size of the
cohort and the transient occurrence of second-degree AV block
Type I and 2:1, no Mobitz II and only one third-degree AV block,
whichwas asymptomatic and reversible, were observed. At visit 3,
no patient had a second- or third-degree AV block. The observed
TABLE 4 | Patient characteristics with potential relevance for cardiac events and








N = 6,998a N = 63b,c N = 120c
Demographics
Age (years), mean ±
SD
39.2 ± 10.52 40.1 ± 10.33 40.6 ± 12.02
Female, n (%) 4,924 (70.36) 26 (41.27) 105 (87.50)
Concomitant medication known to prolong QT interval
SSRI n (%) 707 (10.10) 1 (1.59) 8 (6.67)
TCA n (%) 160 (2.29) 1 (1.59) 2 (1.67)
Amantadine n (%) 69 (0.99) 0 0
Carbamazepine 49 (0.70) 0 2 (1.67)
Fampridine n (%) 523 (7.47) 4 (6.35) 8 (6.67)
Potassium levels at visit 2
< 3.5 mmol/L 32 (0.46) 1 (1.61) 0
≥ 3.5–5.5 mmol/L 6,778 (97.83) 61 (98.39) 119 (99.17)
> 5.5 mmol/L 118 (1.70) 0 1 (0.83)
Cardiac symptomsd during 6h first-dose observation
Patients with
symptoms, n (%)
205 (2.93) 4 (6.35)e 2 (1.67)f
aTwo patients did not receive fingolimod. Information of potassium levels was missing for
70 patients.
b Information of potassium levels was missing for one patient.
cOne of the patients had both, bradycardia and second-degree AV block and is therefore
included in both groups.
dCardiac symptoms are defined as the following MedDRA preferred terms: Angina
pectoris, chest discomfort, dizziness, dyspnoea, dyspnoe exertional, fatigue, palpitations,
syncope, vertigo, vertigo positional, blurred vision.
eFatigue, dizziness, chest discomfort, vertigo.
fPalpitations and dizziness.
incidences of AV block are consistent with those reported from
previous studies, including pivotal and post-marketing studies.
Accordingly, in these other studies, bradycardia occurred in up
to 1.4%, Mobitz type I second-degree AV block (Wenckebach) in
up to 2.6% and 2:1 second-degree AV block in up to 1.4% of the
patients (6–10).
The events identified by continuous ECG monitoring in
the present study were neither associated with severe clinical
symptoms nor with clinically relevant pauses or clinically
relevant drops in heart rate. The time of the initial occurrence
of the second-degree AV block corresponds to the time of the
heart rate nadir. Furthermore, patients with clinical symptoms
had no pathological findings on Holter ECG. The results of the
final analysis further support the assumption that continuous
Holter ECG monitoring does not add clinically relevant value to
patients’ safety.
Not surprisingly, the mean heart rate at baseline of patients
who developed bradycardia after the first dosing was below 60,
whereas in the total population the mean baseline heart rate
was above 70. Further, the incidence of bradycardia was higher
in subgroups with a lower vs. higher BMI and in males vs.
females. The data on EDSS subgroups showed a significantly
higher incidence of bradycardia in patients with an EDSS over
6 and a trend to a higher incidence in the subgroup with an
EDSS below 3.5 compared to an EDSS of 3.5 to 6. It has to be
pointed out, that the distribution of patients between subgroups
was highly imbalanced with a very low number of patients in the
group with EDSS higher than 6. Significant differences between
groups might thus result from group size imbalances rather than
from clinical effects. Our data show that EDSS does not affect the
occurrence of an AV block and heart rate decline. The incidence
of second-degree AV block or higher was highest in patients with
a BMI below 18.5 and lowest in patients with a BMI of 30 and
higher. The incidence also significantly increased with higher age,
i.e., in patients 50 years or older.
According to our results, patients with a low heart rate at
treatment onset may be at a higher risk to develop substantial
bradycardia. The results of an analysis of the heart rate
variability of 81 patients suggest that enhanced parasympathetic
activity is a potential mechanism for the decline in heart
rate. Baseline heart rate therefore was considered to predict
the risk for bradycardia caused by fingolimod (11). In fact,
the cardiovascular effects of fingolimod observed after first
dosing resemble the effects of parasympathetic signaling of the
TABLE 5 | Incidence of AV block during the course of the study.
Fingolimod 0.5mg; n = 6,996 Baseline predose Baseline post dose 7 days post dose
Patients with first-degree AV block, n (%) 124 (1.8) 308 (4.4) 123 (1.8)
Patients with second-degree AV block or higher, n (%) 0 (0.00) 120 (1.70) 0 (0.00)
Mobitz type I (wenckebach)a 0 (0.00) 117 (1.69) 0 (0.00)
AV Block 2:1a 0 (0.00) 42 (0.61) 0 (0.00)
Mobitz type II (mobitz) 0 (0.00) 0 (0.00) 0 (0.00)
Patients with third-degree AV block, n (%) 0 (0.00) 1 (0.01) 0 (0.00)
aA patient might experience both Mobitz type I and 2:1 AV block during the 6-h monitoring.
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FIGURE 3 | Time of the first second-degree AV block (type Mobitz I or 2:1
AV block).
FIGURE 4 | Minimum heart rate from ECG during second-degree AV block
(type Mobitz I or 2:1 AV block).
autonomous nervous system (15). Atropine has been shown
to antagonize the initial heart rate decrease after fingolimod
dosing (25). Cardiac autonomic regulation at baseline was
found to predict the magnitude of fingolimod-initiated heart
rate decrease (26). Heart rate variability assessment can be
used to analyze cardiac autonomic regulation (12, 14, 27).
An increased variability indicates parasympathetic stimulation
while a decrease indicates sympathetic stimulation. After
initiation of fingolimod treatment an initial increase in heart
rate variability was observed that decreases within 3 months
(28), while heart rate remained lower after 3 months of
treatment (29) Hilz et.al. hypothesize that the observed initial
parasympathetic changes under fingolimod might be beneficial
for patients (30). However, after the initial predominance of
parasympathetic signaling, the sympathetic nervous system is
FIGURE 5 | Duration of the longest pause during second-degree AV block
(type Mobitz I or 2:1 AV block).
activated. It was suggested, that this is due to the S1P1
downregulation after initial S1P1 receptor agonism (15, 31).
However, these effects and their clinical relevance in patients
in general and in patients with cardiac risk factors need
further evaluation.
In the present study, a higher BMI was associated with a
lower risk for bradycardia. Moreover, the lower the body weight
was the lower were the minimal heart rates. Similar results
were observed in a small cohort of retrospectively analyzed
patients (32). A low BMI has previously been linked to a
higher incidence of fingolimod-induced adverse events. The
incidence of lymphopenia has been shown to be increased in
patients with a BMI lower than 18.5. The results have to be
interpreted with caution due to the low number of underweight
patients (33). Nevertheless, taken together with the large scale
dataset from the present study, patients with a low BMI might
have a higher incidence of fingolimod-induced adverse events.
However, the overall risk remains low and the observed events
are benign.
Gender differences were observed for the occurrence of
second- and third-degree AV block and bradycardia. Males had
a higher incidence of bradycardia and females had a higher
incidence of AV block, which is in line with previous studies
(14). The difference was statistically significant for both outcome
parameters, but the magnitude of the effect was far more
pronounced with regard to the occurrence of AV blocks. The
time of occurrence of an AV block differed between males and
females, however no difference was observed with respect to
the duration of pauses, indicating that the severity of second-
degree AV block did not differ between males and females.
Gender-specific cardiac differences have been observed before,
which might be explained by hormone-driven regulation of
ion channels (34). However, the pathophysiological basis has
not been fully elucidated (34, 35). The absence of relevant
pauses may contribute to the fact that the vast majority of
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TABLE 6 | Most frequent (serious) adverse events.





Summary of adverse events
Any adverse event 2.288 (32.7) 3,698
Any serious adverse event 160 (2.3) 204
Any adverse event leading to
discontinuation of study drug
68 (1.0) 89
Common adverse events (>1% by PT)
Headache 317 (4.53) 328
Fatigue 228 (3.26) 231
Nausea 144 (2.06%) 146
Nasopharyngitis 137 (1.96%) 137
Dizziness 129 (1.84%) 131
Atrioventricular block second degree 123 (1.76%) 151
Lymphopenia 120 (1.71%) 121
Atrioventricular block first degree 116 (1.66%) 118
Diarrhea 98 (1.40%) 98
Multiple sclerosis relapse 95 (1.36%) 96
Bradycardia 72 (1.03%) 72
Vertigo 70 (1.0%) 71
Common serious adverse events (>0.05% by SOC/PT)
Cardiac disorders 80 (1.14) 99
AV block second-degree (type
Mobitz I or 2:1 AV block)
49 (0.70) 60
Bradycardia (heart rate < 45 bpm) 24 (0.34) 24
Nervous system disorders 41 (0.59) 45
MS relapse 26 (0.37) 26
Investigations 10 (0.14) 10
Electrocardiogram QT prolonged 4 (0.06) 4
Heart rate decreased 4 (0.06) 4
General disorders and administration
site conditions
5 (0.07) 6
Infections and infestations 9 (0.13) 9
Gastrointestinal disorders 6 (0.09) 8
Vascular disorders 5 (0.07) 5
Psychiatric disorders 4 (0.06) 4
PT, Preferred term; SOC, System organ class.
aTwo patients did not receive fingolimod.
events were not associated with any symptoms. While 120
patients had a second-degree AV block type Mobitz I, only
one asymptomatic third-degree block was observed. It can be
assumed that AV blocks associated with fingolimod treatment
initiation are benign, self-limiting and associated with a very low
propensity to progress to a complete AV block. Although affected
by fingolimod, overall AV conduction remains preserved. In the
present study, AV blocks were not preceded by excessive slowing
of heart rate as could be anticipated, but rather followed by
increases in heart rate. This finding suggests that slowing of AV
conduction does not result from an increased parasympathetic
tone but might more likely be due to the positive rate-dependent
electrophysiological effect of fingolimod. A mild direct effect of
fingolimod on the AV node was found in rodents, in which
high S1P1 receptor mRNA expression was present in the AV
node. Fingolimod prolonged the cycle length in isolated AV node
cells by 9% from 230 to 251ms. Under pathological conditions
(such as ischemia/reperfusion), fingolimod did not prolong AV
conduction any further. Therefore, fingolimod-induced AV node
conduction abnormalities seem to be the result of a direct effect
on ion channels expressed in the AV node withmild prolongation
of AV conduction time (36).
CONCLUSIONS
The present study is the largest study to assess the cardiac
effects upon fingolimod treatment initiation. Bradycardia and
AV conduction abnormalities were rare, transient, and benign.
Male patients were at a higher risk for bradycardia during
treatment initiation. Furthermore, a low heart rate before
treatment initiation, low body weight or low BMI increased the
risk for bradycardia. Second- or third-degree AV blocks were
more frequent in older patients as well as in patients with low
BMI. In summary, the study results suggest that fingolimod
therapy is safe in an outpatient setting, without the need of
continuous Holter ECG. ECG monitoring during the first 6 h
after treatment initiation is sufficient to record all clinically
relevant cardiac effects. In summary, the present study confirms
that cardiac effects upon treatment initiation of fingolimod
are rare, benign, and reversible, substantiating the favorable
cardiac safety profile of fingolimod in MS patients without
cardiovascular comorbidities.
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